Clinical trial • Phase I/II • Oncology

CAR20(NAP)-T for Diffuse large B-cell lymphoma | Mantle cell lymphoma | Indolent B-cell lymphoma

Phase I/II trial of CAR20(NAP)-T for Diffuse large B-cell lymphoma | Mantle cell lymphoma | Indolent B-cell lymphoma. None/Not specified-controlled.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Diffuse large B-cell lymphoma | Mantle cell lymphoma | Indolent B-cell lymphoma
Trial Stage
Phase I/II
Drug Modality
Cell therapy

Key dates

Initial CTIS Submission Date
22-08-2024
First CTIS Authorization Date
02-09-2024

Trial design

None/Not specified-controlled Phase I/II trial across 2 sites in Sweden.

Comparator
None/Not specified
Target Sample Size
30

Recruitment

Planned Sample Size
30
Recruitment Window Months
58

Geography

Total Number Of Sites
2
Total Number Of Participants
30

Sweden

Earliest CTIS Part Ii Submission Date
20-05-2024
Latest Decision Or Authorization Date
21-07-2025
Processing Time Days
427
Number Of Sites
2
Number Of Participants
30

Sites

Site Name
Karolinska University Hospital
Department Name
Karolinska universitetssjukhuset, Cellular therapy and allogenic stem cell transplantation, CAST
Contact Person Name
Stephan Mielke
Contact Person Email
stephan.mielke@ki.se
Site Name
Uppsala University Hospital
Department Name
Oncology, Haematology and Endocrine Cancers
Contact Person Name
Gunilla Enblad
Contact Person Email
gunilla.enblad@igp.uu.se

Sponsor

Primary sponsor

Full Name
Uppsala Universitet
Organisation Type
Educational Institution
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
CAR20(NAP)-T
Modality
Cell therapy

Related trials

Other published trials that may interest you.